SHPH SHUTTLE PHARMACEUTICALS HOLDINGS INC Investments/Divestments 8-K Filing 2023 - Manufacturing Success and FDA Approval Shuttle Pharmaceuticals announces successful completion of manufacturing campaign for Ropidoxuridine and FDA approval for Phase II clinical trial in brain cancer patients undergoing radiation therapy.Get access to all SEC 8-K filings of the SHUTTLE PHARMACEUTICALS HOLDINGS INC